Campath-1H in B-chronic lymphocytic leukemia: report on a patient treated thrice in a 3 year period

Monoclonal antibody (mAb) therapy is a novel alternative treatment for lymp hoid malignancies. in this report we present a 55-year-old patient with B-c hronic lymphocytic leukemia, who was initially treated with chlorambucil p. o. and subsequently with cyclophosphamide iv with poor response. Then Campa th-1H mAb was administered, He received three cycles of Campath-1H, over a 3yr period, lasting 12 weeks each, at a final dose of 30mg weekly, on an ou tpatient basis. After each cycle of Campath-1H administration there was a s ignificant decrease of the size of the palpable lymph nodes, spleen and liv er. Restoration of the blood lymphocyte count to normal and a significant d ecrease of the bone marrow lymphocytic infiltration was observed at the end of each cycle. Therefore, a major clinical response was obtained after all cycles. Campath-1H administration was well tolerated without causing any s erious toxicity.